02nd week of 2021 patent applcation highlights part 28 |
Patent application number | Title | Published |
20210009977 | Enzyme Exhibiting a-1,6-Glucosyl Transfer Activity - The present invention relates to an enzyme having α-1,6-glucosyl transfer activity, which can use a partially degraded starch product as a substrate and is heat resistant and suitable for industrial applications; an enzyme preparation for use in manufacturing α-1,6-glucan, comprising the enzyme as an active ingredient; and a method for manufacturing α-1,6-glucan using the enzyme or enzyme preparation. The present invention provides an enzyme having α-1,6-glucosyl transfer activity, which is any one of proteins (a), (b), and (c): (a) a protein consisting of an amino acid sequence of SEQ ID NO: 3; (b) a protein consisting of an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 3; and (c) a protein consisting of an amino acid sequence in which one or several amino acid(s) have been substituted, inserted, deleted and/or added in the amino acid sequence of SEQ ID NO: 3. | 2021-01-14 |
20210009978 | POLYPEPTIDE HAVING COLLAGENASE ACTIVITY AND METHOD FOR PRODUCING THE SAME - One or more embodiments of the present invention provide a novel polypeptide that enables production of a highly uniform polypeptide having collagenase activity. The polypeptide of the one or more embodiments of the present invention is a mutant polypeptide comprising amino acid substitutions in collagenase G or collagenase H. The mutant polypeptide is not modified with an N-linked sugar chain when it is obtained via secretory production in an expression system using a yeast host. | 2021-01-14 |
20210009979 | SUBTILASE VARIANTS AND COMPOSITIONS COMPRISING SAME - The invention relates to subtilase variants and detergent compositions comprising the variants, as well as methods of producing the variants and methods for stabilizing a subtilase variant. | 2021-01-14 |
20210009980 | PLASTIC DEGRADING PROTEASES - The present invention relates to novel proteases, more particularly to protease variants having improved activity compared to the protease of SEQ ID N° 1 and the uses thereof for degrading polyester containing material, such as plastic products. The proteases of the invention are particularly suited to degrade polylactic acid, and material containing polylactic acid. | 2021-01-14 |
20210009981 | NITRILASE MUTANT, CONSTRUCTION METHOD THEREFOR, AND APPLICATION THEREOF - The present invention discloses a nitrilase mutant and its construction method and its application in the synthesis of chiral intermediate of pregabalin in the technical field of bioengineering. The present invention, respectively, takes turnip nitrilase BrNIT and arabidopsis nitrilase AtNIT as parent, using peptide fragment displacement method, displaces the sites 226-286 of BrNIT amino acid sequence and sites 225-285 of AtNIT amino acid sequence with sites 225-285 of | 2021-01-14 |
20210009982 | AGARASE-3,6-ANHYDRO-L-GALACTOSIDASE-ARABINOSE ISOMERASE ENZYME COMPLEX AND METHOD FOR PRODUCTION OF TAGATOSE FROM AGAR USING THE SAME - The present disclosure relates to an enzyme complex of arabinose isomerase, agarase and 3,6-anhydro galactosidase and a method for producing tagatose by degrading agar using the same. By using the enzyme complex according to the present disclosure, agar obtained from marine biomass can be degraded effectively and useful physiologically active substances such as tagatose can be obtained effectively therefrom. | 2021-01-14 |
20210009983 | ACETYL-COA CARBOXYLASE VARIANTS - The disclosure relates to acetyl-CoA carboxylase (ACC) variants and host cells expressing them for the production of malonyl-CoA derived compounds including fatty acid derivatives. Further contemplated are methods of producing increased amounts of malonyl-CoA derived compounds and related cell cultures. | 2021-01-14 |
20210009984 | THERAPEUTIC ENZYME FUSION PROTEIN HAVING A NOVEL STRUCTURE AND USE THEREOF - A fusion protein of a dimeric therapeutic enzyme and an immunoglobulin Fc region, a preparation method thereof, and a composition containing the fusion protein are disclosed. | 2021-01-14 |
20210009985 | SYSTEMS AND METHODS FOR GROWING A BIOFILM OF PROBIOTIC BACTERIA ON SOLID PARTICLES FOR COLONIZATION OF BACTERIA IN THE GUT - The present invention provides a method, wherein the method forms a biofilm, wherein the biofilm comprises a population of at least one bacterial strain attached to particles, wherein the biofilm is configured to colonize a gut of a subject in need thereof for at least five days, when ingested by the subject, the method comprising: a. obtaining a population comprising at least one strain of bacteria; b. inoculating a growth medium containing particles with the population comprising at least one strain of bacteria; c. incubating the particles with the population comprising at least one bacterial strain for a time sufficient for the population of at least one strain of bacteria to attach to the particles; and d. culturing the population comprising at least one strain of bacteria attached to the particles in a growth medium, for a time sufficient to form a biofilm. | 2021-01-14 |
20210009986 | SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING - The disclosure provides for systems, methods, and compositions for targeting and editing nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a RNA-targeting Cas13 protein, at least one guide molecule, and at least one adenosine deaminase protein or catalytic domain thereof. | 2021-01-14 |
20210009987 | RNA-TARGETING KNOCKDOWN AND REPLACEMENT COMPOSITIONS AND METHODS FOR USE - Disclosed are compositions and methods for specifically targeting and knocking down pathogenic RNA molecules which lead to toxic gain-or-loss-of-function mutations while also replacing the targeted, and knocked down, gene with a therapeutic replacement gene. | 2021-01-14 |
20210009988 | MODULATING LACTOGENIC ACTIVITY IN MAMMALIAN CELLS - The present disclosure relates to methods, cells and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interests, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have modulated lactogenic activity. The present disclosure also relates to methods and compositions for modulating pyruvate kinase muscle (PKM) expression (e.g., PKM-1 expression) in a mammalian cell to thereby reduce or eliminate the lactogenic activity of the cell, as well compositions comprising a cell having reduced or eliminated lactogenic activity and methods of using the same. | 2021-01-14 |
20210009989 | METHOD FOR EXTRACTING NUCLEIC ACIDS - A method for extracting nucleic acids using suitable solid supports, for example silica-based. In particular, the method includes a step of capturing nucleic acids by placing the sample in contact with a suitable solid support, characterized in that, prior to the capture step, said method includes a step of treating the sample with at least one reagent for masking the amine or carboxylic acid functional groups of the proteins and/or polysaccharides of the sample. | 2021-01-14 |
20210009990 | METHODS FOR ISOLATING NUCLEIC ACIDS WITH SIZE SELECTION - Disclosed here is a method for isolating nucleic acids from a biological sample, comprising: (a) contacting a first composition comprising nucleic acids obtained from a biological sample with a first matrix under a low-stringency binding condition having less than 1% aliphatic alcohols that binds less than 5% of nucleic acids of shorter than about 118 bp and more than 30% of nucleic acids longer than about 194 bp to a first matrix; and (b) contacting a second composition comprising remainder of the first composition with a second matrix under a high-stringency binding condition having less than 1% aliphatic alcohol that binds more than 70% of nucleic acids longer than about 72 bp and 30% of nucleic acids longer than about 50 bp to the second matrix. Further disclosed is a kit for isolating nucleic acids from a biological sample, comprising (a) a first binding buffer for establishing a low-stringency binding condition having less than 1% aliphatic alcohols that binds less than 5% of nucleic acids shorter than about 118 bp and more than 30% of nucleic acids longer than about 194 bp to a matrix, and (b) a second binding buffer for establishing a high-stringency binding condition having less than 1% aliphatic alcohol that binds more than 70% of nucleic acids longer than about 72 bp and 30% of nucleic acids longer than about 50 bp to the matrix. | 2021-01-14 |
20210009991 | METHODS AND APPARATUSES FOR CHIP-BASED DNA ERROR REDUCTION - Methods and apparatus relate to reduction of sequence errors generated during synthesis of nucleic acids on a microarray chip. The error reduction can include synthesis of complementary stands (to template strands), using a short universal primer complementary to the template strands and polymerase. Heteroduplex can be formed be melting and re-annealing complementary stands and template strands. The heteroduplexes containing a mismatch can be recognized and cleaved by a mismatch endonuclease. The mismatch-containing cleaved heteroduplexes can be removed from the microarray chip using a global buffer exchange. The error free synthetic nucleic acids generated therefrom can be used for a variety of applications, including synthesis of biofuels and value-added pharmaceutical products. | 2021-01-14 |
20210009992 | COMPOSITIONS AND METHODS FOR MULTIPLEXED QUANTITATIVE ANALYSIS OF CELL LINEAGES - Compositions and methods are provided for measuring population size for a plurality of clonal cell populations in the same individual, e.g., for measuring tumor size for a plurality of clonally independent tumors within the same individual. A subject method can include: (a) contacting an individual with a plurality of cell markers that are heritable and distinguishable from one another, to generate a plurality of distinguishable lineages of heritably marked cells; (b) after sufficient time has passed for the heritably marked cells to undergo at least one round of division, detecting and measuring quantities of at least two of the plurality of cell markers present in the contacted tissue, thereby generating a set of measured values; and (c) using the set of measured values to calculate the number of heritably marked cells that are present (e.g., for at least two of the distinguishable lineages of heritably marked cells). | 2021-01-14 |
20210009993 | METHOD FOR AFFINITY MATURATION OF ANTIBODIES - The present invention relates to a novel method of generating libraries of polynucleotides encoding a framework region and at least one adjacent complementarity determining region (CDR) of an antibody of interest. These libraries are suitable for use in affinity maturation procedures in order to obtain maturated antibodies with improved characteristics compared to the parent antibody. | 2021-01-14 |
20210009994 | DIRECT OLIGONUCLEOTIDE SYNTHESIS ON CELLS AND BIOMOLECULES - The invention is directed to methods for synthesizing oligonucleotides direction on biomolecules or cells living or fixed. In some embodiments, template-free enzymatic synthesis is implemented under biological conditions with successive cycles of (i) enzymatic addition of a 3′-O-blocked nucleoside triphosphate and (ii) enzymatic deblocking of the incorporated nucleotide to regenerate a free 3′ hydroxyl. The invention has applications in single-cell cDNA library construction and analysis. | 2021-01-14 |
20210009995 | POLYRIBONUCLEOTIDE CONTAINING DEUTERATED NUCLEOTIDES - The present disclosure provides polyribonucleotides, in particular polyribonucleotides, which comprise deuterated adenosine, cytidine, guanosine, and/or uridine residues and which show reduced immunogenicity and/or enhanced expression, and methods of using such polyribonucleotides for the therapy of diseases. | 2021-01-14 |
20210009996 | TREATING AND PREVENTING MICROBIAL INFECTIONS - The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease. | 2021-01-14 |
20210009997 | HOMOLOGOUS RECOMBINATION DIRECTED GENOME EDITING IN EUKARYOTES - Disclosed herein are synthetic nucleic acids comprising a nucleic acid sequence that encodes an ANAGO that is a species-specific to a eukaryote, and compositions comprising ANAGO and donor molecules for use in homologous recombination directed targeted gene editing in the eukaryote. | 2021-01-14 |
20210009998 | MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES - The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34 | 2021-01-14 |
20210009999 | AMPHIPHILIC POLYNUCLEOTIDES - Compositions and methods disclosed herein can help provide improved delivery of non-natural therapeutic nucleotides for the treatment of diseases such as cancer. An example composition includes an assembly of amphiphilic polynucleotides, where each amphiphilic polynucleotide includes an aptamer portion, a first nucleotide portion, and a second nucleotide portion. | 2021-01-14 |
20210010000 | NUCLEIC ACID WITH REDUCED TOXICITY - An object of the invention is to provide a low toxicity antisense nucleic acid medicine that can modulate expression of a target transcriptional product in the central nervous system and other sites of a subject. Provided is a low toxicity composition for modulating expression of a target transcriptional product in a site such as the central nervous system of a subject, having a nucleic acid complex formed by annealing together a first nucleic acid strand having an antisense oligonucleotide region with respect to the target transcriptional product, and a second nucleic acid strand having a complementary region that is complementary to at least part of the first nucleic acid strand. | 2021-01-14 |
20210010001 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA - Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin. | 2021-01-14 |
20210010002 | NUCLEIC ACID MOLECULES FOR PSEUDOURIDYLATION - The invention relates to nucleic acid molecules for pseudouridylation of a target uridine in a target RNA in a mammalian cell, wherein the nucleic acid molecule comprises a guide region capable of forming a partially double stranded nucleic acid complex with the target RNA comprising the target uridine, wherein the partially double stranded nucleic acid complex is capable of engaging a mammalian pseudouridylation enzyme, wherein the guide region assists in positioning the target uridine in the partially double stranded nucleic acid complex for it to be converted to a pseudouridine by the mammalian pseudouridylation enzyme. | 2021-01-14 |
20210010003 | Combination comprising immunostimulatory oligonucleotides - The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA. | 2021-01-14 |
20210010004 | INHIBITION OF POLYOMAVIRUS REPLICATION - The invention relates to antisense molecules and methods for modulating splicing of polyomavirus T antigen pre-mRNA. In one aspect the invention relates to an antisense oligonucleotide 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length which comprises a sequence that is the reverse complement of a contiguous stretch of at least 12 nucleobases of a polyomavirus T-antigen pre-mRNA and which antisense oligonucleotide can modulate splicing of said T-antigen pre-mRNA in a cell. | 2021-01-14 |
20210010005 | METHODS AND COMPOSITIONS FOR TREATING BILE DUCT PAUCITY-ASSOCIATED CONDITIONS - This disclosure relates to oligonucleotides, compositions and methods useful for reducing CTNNB1 expression, particularly in hepatocytes, for the treatment of bile duct paucity-associated conditions. Disclosed oligonucleotides for the reduction of CTNNB1 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of CTNNB1 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver. | 2021-01-14 |
20210010006 | INCREASED NUCLEIC ACID-GUIDED CELL EDITING VIA A LEXA-RAD51 FUSION PROTEIN - The present disclosure provides compositions and methods to increase the percentage of edited yeast cells in a cell population when employing nucleic acid-guided editing, and automated multi-module instruments for performing these methods. | 2021-01-14 |
20210010007 | METHOD FOR PREPARING DNA UNIT COMPOSITION, AND METHOD FOR CREATING CONCATENATED DNA - Provided are: a method for preparing a DNA unit composition in which the mol number of a plurality of DNA units is more uniform, and a method for creating concatenated DNA. The method for preparing a DNA unit composition has: a step for preparing solutions which contain a plurality of DNA units to which an added sequence is linked, and preparing a solution for each type of DNA unit and a step for, after preparing each of the solutions, measuring the concentration of the DNA unit in each of the solutions in a state where the added sequence is linked to the DNA unit, and on the basis of the results thereof, fractionating each of the solutions and making the mol number of the DNA unit in each of the solutions closer to being identical to one another. | 2021-01-14 |
20210010008 | Method for Introducing Mutations - The present invention relates to a method for introducing mutations into at least one target nucleic acid molecule comprising (a) providing at least one sample comprising at least one target nucleic acid molecule; and (b) amplifying the at least one target nucleic acid molecule using a low bias DNA polymerase. The present further relates to a use of a low bias DNA polymerase in a method for introducing mutations into one or more nucleic acid molecule(s), a group of sample tags, a method for designing the group of sample tags, a computer readable medium, and a method for preferentially amplifying target nucleic acid molecules. | 2021-01-14 |
20210010009 | Systematic Creation of Fluorescent Fusion Polypeptides - A method for creating a plasmid for use in producing a chimeric antibody, comprising (a) receiving a FAB region of the antibody; (b) receiving a fluorescent protein; (c) receiving a linker having length of at least 5 amino acids; (d) using the Gibson assembly process to join the FAB region, the fluorescent protein, and the linker into an expression plasmid. | 2021-01-14 |
20210010010 | Fungal Chaperone Proteins - The present invention relates to fungal host cells comprising nucleic acid constructs comprising a heterologous promoter operably linked to polynucleotidea encoding a chaperone, nucleic acid constructs comprising a polynucleotide encoding a chaperone, and methods for producing polypeptides of interest. | 2021-01-14 |
20210010011 | VECTORS AND METHODS FOR IMPROVED PLANT TRANSFORMATION EFFICIENCY - Methods and compositions for improved bacterial-mediated plant transformation are provided. The methods generally allow plant transformation with reduced vector backbone integration and a high frequency of low-copy transformation events. Vectors for achieving these results are described, as are methods for their use. | 2021-01-14 |
20210010012 | USE OF MORPHOGENIC FACTORS FOR THE IMPROVEMENT OF GENE EDITING - Methods and compositions are provided for the improvement of double-strand-break-inducing agent activity in eukaryotic cells, through the usage of one or more morphogenic factors or developmental genes. The morphogenic factor may be provided to the same cell or to a different cell than that comprising or receiving the double-strand-break-inducing agent. The morphogenic factor may be provided to a cell as a polynucleotide composition on a recombinant vector, and may be placed on the vector outside of a T-DNA border. The morphogenic factor may be provided via an upregulation of an endogenous gene. The morphogenic factor, or the double-strand-break-inducing agent, may further comprise a cell penetrating peptide. The morphogenic factor may be co-introduced with a vector comprising RepA. | 2021-01-14 |
20210010013 | FAD2 GENES AND MUTATIONS - The present disclosure provides fatty acid desaturase 2 (FAD2) genes and plants and/or plant cells bearing one or more mutations in two or more FAD2 genes; as well as methods of making and using such plants. In some embodiments, plants producing seed oil with high oleic acid content are provided. | 2021-01-14 |
20210010014 | PEANUT WITH REDUCED ALLERGEN LEVELS - Genetic constructs are provided to reduce or eliminate the allergenicity of peanuts. The constructs function by generating interfering RNA and/or by directing deletion using the CRISPR/Cas9 system. The constructs may be used in the production of genetically modified plants, plant parts and cells with reduced allergenicity. | 2021-01-14 |
20210010015 | HETEROLOGOUS PRODUCTION OF PSILOCYBIN - A recombinant host cell is disclosed for producing psilocybin and related compounds, such as metabolic intermediates of the psilocybin biosynthesis. Also provided is a method of producing psilocybin and its synthesis intermediates and related compounds, such as metabolic intermediates of the psilocybin biosynthesis, in the host cell, as well as a production system for producing them. | 2021-01-14 |
20210010016 | PLANTS WITH ALTERED PRODUCTION OF BIOMASS CONSTITUENTS AND METHODS OF USE - Nucleic acid constructs, and cells, plants, and plant parts containing such constructs, for modifying content of biomass constituents (e.g, lignin, hemicellulose, and/or cellulose) in plants via altered expression of certain transcription factors (regulators). Lignin, hemicellulose, and/or cellulose content can be decreased by increasing expression of certain negative regulators, or by decreasing expression of positive regulators. Alternatively, lignin, hemicellulose, and/or cellulose content can be increased by decreasing expression of negative regulators, or by increasing expression of positive regulators. | 2021-01-14 |
20210010017 | FOOD COMPOSITIONS COMPRISING MILK PROTEINS PRODUCED IN TRANSGENIC PLANTS - The disclosure describes a transgenic dicot or monocot plant having bovine milk protein(s) and methods of producing the transgenic dicot or monocot plant containing bovine milk protein(s). These transgenic dicot or monocot plants can express and produce bovine milk protein(s). The methods involve introducing a recombinant DNA construct expressing a bovine milk protein into a dicot or monocot plant, obtaining the dicot or monocot plant containing the bovine milk protein(s) from a recombinant DNA construct, cultivating and harvesting the transgenic dicot or monocot plant, and extracting and purifying the bovine milk protein(s) from transgenic dicot or monocotyledonous plants. The disclosure also describes food compositions comprising milk proteins produced using the transgenic dicot or monocot plants described herein. | 2021-01-14 |
20210010018 | NUCLEOTIDE SEQUENCE AND USE THEREOF IN INCREASING THE DENSITY OF SECRETORY GLANDULAR TRICHOMES IN PLANTS - The present invention discloses a nucleotide sequence and use thereof in increasing the density of secretory glandular trichomes in plants. The nucleotide sequence is selected from the group consisting of: 1) a nucleotide sequence according to any one of SEQ ID NOs: 1, 3 and 5; 2) a nucleotide sequence derived from the nucleotide sequence according to any one of SEQ ID NOs: 1, 3 and 5 through substitution, deletion or addition of one or more nucleotides; 3) a nucleotide sequence having at least 80% homology with any one of SEQ ID NOs: 1, 3 and 5. The present invention significantly increases the density of secretory glandular trichomes by transferring any one of the above nucleotide sequences into the plants by means of genetic engineering. Therefore, the invention shows great potential in insect resistance and production of specific metabolites, and has extremely high practical application value. | 2021-01-14 |
20210010019 | PESTICIDAL GENES AND METHODS OF USE - Compositions having pesticidal activity and methods for their use are provided. Compositions include isolated and recombinant polypeptide sequences having pesticidal activity, recombinant and synthetic nucleic acid molecules encoding the pesticidal polypeptides, DNA constructs comprising the nucleic acid molecules, vectors comprising the nucleic acid molecules, host cells comprising the vectors, and antibodies to the pesticidal polypeptides. Nucleotide sequences encoding the polypeptides provided herein can be used in DNA constructs or expression cassettes for transformation and expression in organisms of interest, including microorganisms and plants. The compositions and methods provided herein are useful for production of organisms with enhanced pest resistance or tolerance. Transgenic plants and seeds comprising a nucleotide sequence that encodes a pesticidal protein of the invention are also provided. Such plants are resistant to insects and other pests. Methods are provided for producing the various polypeptides disclosed herein, and for using those polypeptides for controlling or killing a pest. | 2021-01-14 |
20210010020 | LEPIDOPTERAN-ACTIVE CRY1DA1 AMINO ACID SEQUENCE VARIANT PROTEINS - Engineered Cry1Da amino acid sequences are provided that exhibit improved Lepidopteran insecticidal activity and an enhanced Lepidopteran spectrum compared to the naturally occurring Cry1Da protein toxin. Polynucleotide sequences intended for use in expression of the improved proteins in plants are also provided. Particular embodiments provide compositions containing insect inhibitory amounts of the engineered proteins, as well as recombinant plants, plant parts, and seeds containing polynucleotide constructs encoding one or more of the improved engineered proteins. | 2021-01-14 |
20210010021 | VIRAL AND NON-VIRAL NANOPLASMID VECTORS WITH IMPROVED PRODUCTION - A method for improving the replication of a covalently closed circular plasmid is provided. The method includes providing a covalently closed circular plasmid having a Pol I-dependent origin of replication, and an insert including a structured DNA sequence selected from the group consisting of inverted repeat sequence, direct repeat sequence, homopolymeric repeat sequence, eukaryotic origin of replication or eukaryotic promoter enhancer sequence, wherein the structured DNA sequence is located at a distance of less than 1000 by from the Pol I-dependent origin of replication in the direction of replication. The method also includes modifying the covalently closed circular recombinant molecule such that the Poi I-dependent origin of replication is replaced with a Pol III-dependent origin of replication, whereby the resultant Pol III-dependent origin of replication covalently closed circular plasmid has improved replication. An antibiotic marker free covalently closed circular recombinant DNA molecule is also provided. | 2021-01-14 |
20210010022 | NOVEL NUCLEIC ACID CONSTRUCT - The invention relates to a nucleic acid construct for bi-allelic conditional modification of a target gene and methods of use thereof. | 2021-01-14 |
20210010023 | USE OF HAPLOTYPE OF SNP SITE ASSOCIATED WITH HYPOXIA TOLERANCE IN BREEDING OF MEGALOBRAMA AMBLYCEPHALA - A method of breeding a hypoxia-tolerant | 2021-01-14 |
20210010024 | SYNPIII, A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN RETINAL PIGMENT EPITHELIUM - The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1000 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in cells of the retinal pigment epithelium of a gene when operatively linked to a nucleic acid sequence coding for said gene. | 2021-01-14 |
20210010025 | TREATMENT OF OCULAR DISEASES WITH HUMAN POST-TRANSLATIONALLY MODIFIED VEGF-TRAP - Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) therapeutic VEGF-Trap (VEGF-Trap | 2021-01-14 |
20210010026 | RETROVIRAL TRANSDUCTION USING POLOXAMERS - The present invention relates to a method for transducing a target cell, the method comprising the step of contacting a target cell with a retroviral vector and a poloxamer having a molecular weight of 12.8 kDa to about 15 kDa. Further, the invention relates to the use of a poloxamer as defined herein, optionally in combination with a polycationic substance as defined herein, for transducing a target cell with a retroviral vector and a kit comprising a retroviral vector, a poloxamer as defined herein and, optionally, instructions for use. | 2021-01-14 |
20210010027 | COMPOSITIONS AND METHODS FOR GENERATING ADENO-ASSOCIATED VIRAL VECTORS WITH UNDETECTABLE CAPSID GENE CONTAMINATION - In one aspect, the present invention provides an intron-modified capsid expression cassette useful for generating adeno-associated virus (AAV) vector particles. In another aspect, the present invention provides a method of reducing the immune response in a mammalian subject undergoing treatment with an AAV vector. | 2021-01-14 |
20210010028 | INSECT CELL MANUFACTURED PARTIAL SELF-COMPLEMENTARY AAV GENOMES - The present disclosure is directed to parvovirus genomes; plasmid vectors encoding parvovirus genomes, and particles and populations thereof; as well as methods of their production and use. | 2021-01-14 |
20210010029 | ADENOVIRAL VECTORS COMPRISING PARTIAL DELETIONS OF E3 - This disclosure provides replication-incompetent adenoviral vectors useful in vaccine development and gene therapy. The disclosed vectors comprise a selective deletion of E3 and are particularly useful for preparation of vaccines development and for gene therapy using toxic transgene products that result in vector instability that occurs when the entire E3 domain is deleted. | 2021-01-14 |
20210010030 | METHOD FOR REPROGRAMMING SOMATIC CELLS - The disclosure relates to a method for reprogramming somatic cells from mammalian cells including human, bat and equine cells. The inventors have identified an original combination of reprogramming factors for use in methods for reprogramming somatic cells into stem cells from various species, such as bat, bovine, equine and human species. In particular, the disclosure relates to an in vitro method for preparing stem cells reprogrammed from mammalian somatic cells, said method comprising culturing mammalian somatic cells and expressing at least the following combination of reprogramming factors: (i) a reprogramming factor encoded by ESRRB gene, (ii) a reprogramming factor encoded by CDX-2 gene, and, (iii) a reprogramming factor encoded by c-MYC gene, under appropriate conditions for reprogramming said mammalian somatic cells into stem cells. | 2021-01-14 |
20210010031 | LENTIVIRAL VECTORS FOR HIGH-TITER TRANSDUCTION OF PRIMARY HUMAN CELLS - Aspects of the disclosure relate to packagable RNA constructs with minimal intervening viral sequences. These constructs can be used to generate lentiviral viruses encoding large genes capable of transducing primary human cells. | 2021-01-14 |
20210010032 | GENE THERAPIES FOR LYSOSOMAL DISORDERS - The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding beta-Glucocerebrosidase (GBA) or a portion thereof, Lysosomal Membrane Protein 2 (LIMP2), Prosaposin, or any combination of the foregoing. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof | 2021-01-14 |
20210010033 | RECOMBINANT HVT VECTORS EXPRESSING MULTIPLE ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF - The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors and polyvalent vaccines comprising the recombinant HVT vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors. | 2021-01-14 |
20210010034 | TRANSIENT CELLULAR REPROGRAMMING FOR REVERSAL OF CELL AGING - Provided herein are methods and compositions useful in cellular rejuvenation, tissue engineering, and regenerative medicine. Compositions and methods for rejuvenating aged cells and tissues to restore functionality are disclosed. In particular, cells are rejuvenated by transient exposure to non-integrated mRNAs encoding reprogramming factors to rejuvenate cells while retaining cells in a differentiated state. | 2021-01-14 |
20210010035 | PRODUCTION OF MANOOL - Described herein are methods of producing (+)-manool, the methods including: contacting geranylgeranyl diphosphate with a copalyl diphosphate (CPP) synthase to form a (9S, 10S)-copalyl diphosphate and contacting the CPP with a sclareol synthase enzyme to form (+)-manool and derivatives thereof. Also described herein are nucleic acids encoding CPP synthases and sclareol synthases for use in the methods. Further described herein are expression vectors and non-human host organisms and cells including nucleic acids encoding a CPP synthase and a sclareol synthase as described herein. | 2021-01-14 |
20210010036 | PRETREATMENT WITH LIGNOSULFONIC ACID - A process for converting lignocellulosic biomass to glucose or ethanol includes subjecting the lignocellulosic biomass to a lignosulfonic acid pretreatment, wherein the lignosulfonic acid has a concentration of sulfonate groups in acid form that is greater than 0.02 mol/L and a total amount of sulfur dioxide is greater than 15 wt % based on dry weight of lignocellulosic biomass. | 2021-01-14 |
20210010037 | METHODS AND SYSTEMS FOR CHEMOAUTOTROPHIC PRODUCTION OF ORGANIC COMPOUNDS - The present disclosure identifies pathways, mechanisms, systems and methods to confer chemoautotrophic production of carbon-based products of interest, such as sugars, alcohols, chemicals, amino acids, polymers, fatty acids and their derivatives, hydrocarbons, isoprenoids, and intermediates thereof, in organisms such that these organisms efficiently convert inorganic carbon to organic carbon-based products of interest using inorganic energy, such as formate, and in particular the use of organisms for the commercial production of various carbon-based products of interest. | 2021-01-14 |
20210010038 | ENZYMATIC PROCESS FOR PRODUCTION OF MODIFIED HOP PRODUCTS - The present invention relates to a process for producing a beer bite ring agent via enzyme catalyzed bioconversion of hop-derived isoalpha acids to dihydro-(rho)-isoalpha acids. | 2021-01-14 |
20210010039 | RECOMBINANT CELL AND METHOD OF PRODUCING ITACONIC ACID - A recombinant cell and a method of producing itaconic acid using such recombinant cell. The recombinant cell is of the genus | 2021-01-14 |
20210010040 | D-Lactate Dehydrogenase, Engineered Strain Containing D-Lactate Dehydrogenase and Construction Method and Use of Engineered Strain - The present invention provides D-lactate dehydrogenase, an engineered strain containing the D-lactate dehydrogenase and a construction method and use of the engineered strain. The present invention discloses a D-lactate dehydrogenase which has unique properties and is from | 2021-01-14 |
20210010041 | METHOD OF PRODUCING AMIDE COMPOUND - Provided is a method of producing an amide compound, the method including: obtaining a reaction solution containing an amide compound by bringing a microbial cell containing nitrile hydratase, or a processed product of the microbial cell, into contact with a nitrile compound in an aqueous medium in a first reactor; and causing the obtained reaction solution containing an amide compound to react in a second reactor having a plug-flow region, in which the Reynolds number in the second reactor is controlled to from 5 to 1,000. | 2021-01-14 |
20210010042 | ATP PHOSPHORIBOSYLTRANSFERASE VARIANT AND METHOD FOR PRODUCING L-HISTIDINE USING THE SAME - The present disclosure relates to an ATP phosphoribosyltransferase (HisG) protein and a method for producing histidine using the same. | 2021-01-14 |
20210010043 | METHOD OF PRODUCTION - The present invention in the field of oligosaccharide production provides a method of producing oligosaccharides of useful lengths without producing substantial amounts of monosaccharides and disaccharides (illustrated by FIG. | 2021-01-14 |
20210010044 | Enzymatic Preparation Method of Inclusion Complexes of Tributyrin - The disclosure relates to an enzymatic preparation method of inclusion complexes of tributyrin, and belongs to the technical field of oil microencapsulation. The disclosure combines enzymatic synthesis of cyclodextrin and inclusion of tributyrin with cyclodextrin, including enzymatic preparation of cyclodextrin with a CGT enzyme. Tributyrin is added in the preparation process; after reaction, Tween is added, and homogenization and spray drying are carried out. The effect of the finally obtained tributyrin powder is much better than that of single inclusion of tributyrin with cyclodextrin. The disclosure is simple in process, low in cost and convenient in operation; reaction processes are free of toxicity and pollution; there are no toxic reagent residues; the inclusion effect is obvious, and better utilization of a nutritional additive tributyrin in actual production is facilitated. | 2021-01-14 |
20210010045 | METHOD FOR PRODUCING GALACTOOLIGOSACCHARIDE - Provided is a method for improving the production amount of a tri- or higher galactooligosaccharide and the reaction rate by a method for producing a galactooligosaccharide characterized by allowing β-galactosidase to react with a substrate in the presence of 5 to 60 mM sodium ions and 0.5 to 8 mM magnesium ions. | 2021-01-14 |
20210010046 | ADENOSINE-HIGH PRODUCTION PAECILOMYCES HEPIALI CS4 STRAIN ISOLATED FROM CORDYCEPS SINENSIS - Provided is an adenosine-high production. | 2021-01-14 |
20210010047 | METHOD FOR PREPARING ACTIVE PROTEIN HYDROLYSATES BY HYDROLYZING CEREAL PROTEINS WITH MALT TOGETHER WITH PROTEASES - This disclosure relates to the technological field of nutrient food, particularly relates to a method for preparing active protein hydrolysates by hydrolyzing cereal proteins with malt together with proteases, including the following steps: (1) grinding the malt, obtaining the malt flour; (2) hydrolyzing cereal proteins with the malt flour together with proteases to prepare active protein hydrolysates. The present invention uses the malt flour together with proteases to hydrolyze cereal proteins, which can effectively reduce the consumption of proteases and save the cost, moreover, aminopeptidases and carboxypeptidases in the malt are able to hydrolyze peptide linkages from the ends of proteins, and the bitter hydrophobic amino acids are cut off, thus effectively decreasing the bitterness of the products, on the other hand, which can increase the additional values of the malt, providing its new applications. | 2021-01-14 |
20210010048 | METHOD OF PREPARING CORN GLYCOPEPTIDES, AND PRODUCT AND USE THEREOF - A method for preparing corn glycopeptides, and a product and use thereof, and belongs to the technical field of food and medicine production. The method for preparing corn glycopeptides includes the preparation of corn peptides powder and the glycosylation reaction between corn peptides and amino sugar; the preparation raw material of the corn peptides powder is a corn protein rich in branched chain amino acids; and the corn peptides and the amino sugar are subjected to the glycosylation reaction catalyzed by a transglutaminase, and finally the corn glycopeptides is obtained. The method for preparing corn glycopeptides provided by the present disclosure is simple; and the prepared corn glycopeptides have antagonistic and protective effects on alcoholic liver injury, and can be applied to the preparation of related foods, medicines and health care products. | 2021-01-14 |
20210010049 | METHOD FOR PRODUCING ASTAXANTHIN - Efficiency of production method for producing astaxanthin by culturing microalgae is improved. A method for producing astaxanthin in which astaxanthin is produced in inner of algae by culturing a microalga, wherein a light irradiation during a green stage culturing of the microalga is performed by using both a blue LED of peak wavelength from 420 to 500 nm and a red LED of peak wavelength from 620 to 690 nm, and having a ratio of photon flux density of the blue LED to the red LED to be 2:3 to 20:1. It is preferable that the photon flux density of the blue LED is from 5 to 200 μmol/m | 2021-01-14 |
20210010050 | ONE POT ELECTRO-CROSS-LINKING OF A PROTEIN FOR THE DEVELOPMENT OF A PROTEIN-BASED BIOSENSOR - Disclosed is a liquid composition including a protein, a polyphenol and a morphogen; to a solid composition including the cross-linked product of a protein and a polyphenol; to a biosensor and a biofuel cell including the solid composition bound to a surface of an electrochemical probe; to a process for the detection of an analyte with the biosensor; and to the use of a ferrocene as a morphogen in an electrodeposition process. | 2021-01-14 |
20210010051 | DETECTION METHOD AND DETECTION PROBE FOR COLIBACTIN AND COLIBACTIN-PRODUCING BACTERIA - The present invention provides a method and probe for determining colibactin and a colibactin-producing bacterium. According to the present invention, there is provided a fluorescent probe for detecting myristoyl asparagine using, for example, a tissue sample and a fecal sample and detecting enzyme activity of ClbP. | 2021-01-14 |
20210010052 | MARKER AND METHOD FOR DETERMINATION OF PARKINSON'S DISEASE - The present invention relates to a method for simply diagnosing the progress of disease condition of a Parkinson's disease patient. Provided are a method for determining Parkinson's disease using the number of one or more intestinal bacteria selected from the group consisting of | 2021-01-14 |
20210010053 | ASSAYS FOR IMPROVING AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING ACCURACY - Phenotypic antimicrobial susceptibility testing (AST), the gold-standard diagnostic that indicates whether an antimicrobial will be clinically effective, often suffer the slowest times-to-result for the most resistant pathogens. Here we introduce novel assays to be performed in parallel with standard AST assays that enable rapid, same-shift reporting of AST results for a plurality of pathogens. The assays developed here are further capable of detecting resistance to carbapenems, the most powerful class of beta-lactams commonly used as “last-resort” antimicrobials. | 2021-01-14 |
20210010054 | DEVICE FOR TESTING BACTERIUM, AND METHOD FOR TESTING BACTERIUM - Provided is a technique that enables accurate determination as to whether growth of bacteria has occurred or been inhibited. A bacteria test apparatus according to the present disclosure includes a microscope optical system which captures images of bacteria in each of a plurality of wells at a plurality of time points, the plurality of wells each holding a culture solution containing an antibacterial drug and the bacteria, an arithmetic unit which calculates a feature of luminance value for each of the images of the bacteria, a determination unit which determines whether growth of the bacteria has occurred in the wells based on a change in the feature of luminance value, and a display device which displays a determination result output from the determination unit. The arithmetic unit calculates, as the feature of luminance value, a feature including at least one of a mean, a median, or a mode (see FIG. | 2021-01-14 |
20210010055 | METABOLIC ENZYME ACTIVITY AND DISULFIDE BOND REDUCTION DURING PROTEIN PRODUCTION - The present disclosure relates to the use of host cell protein biomarkers to assess disulfide bond reduction in compositions comprising a protein of interest. In some embodiments, the disclosure relates to methods of predicting the occurrence of disulfide bond reduction or low molecular weight protein species in compositions comprising a protein of interest, wherein the expression or activity level of at least one host cell protein is measured and provides a benchmark value associated with the occurrence of disulfide bond reduction or low molecular weight species of said protein of interest. In some embodiments, the disclosure relates to methods of producing a protein of interest, wherein host cells capable of producing the protein of interest are cultured, the expression or activity level of at least one host cell protein is measured, and downstream isolation of the protein of interest is informed by the host cell protein measurements. | 2021-01-14 |
20210010056 | GLYCOSYLATION MODIFICATION OF BIOACTIVE COMPOUNDS AND DRUGS BY PLANT GLYCOSYLTRANSFERASES (UGTS) - In alternative embodiments, provided are methods for the glycosylation modification of bioactive compounds and drugs using isolated, recombinant or genetically modified uridine diphosphate glycosyl-transferases (UGTs). In alternative embodiments, provided are methods for modifying UGTs to generate recombinant UGTs with altered donor and/or acceptor specificities. In alternative embodiments, provided are methods for screening for recombinantly engineered UGTs with new or altered properties, for example, for new or altered donor and/or acceptor specificities, where in alternative embodiments the screening comprise use of bacterial, yeast or baculovirus expression system. | 2021-01-14 |
20210010057 | AMINO ACID-SENSING DIGUANYLATE CYCLASE AND METHODS OF USE - Provided are SpdE polypeptides and variants and nucleic acids encoding the SpdE polypeptides and variants. Also provided are vectors including one or more nucleic acids encoding a SpdE polypeptide or variant and cells including a nucleic acid encoding the SpdE polypeptide or variant, as well as cells expressing a SpdE polypeptide or variant and compositions including such cells and a pharmaceutically acceptable carrier. Finally, methods of detecting presence and/or amount of one or more amino acids in a sample are provided. The methods include contacting the sample with a SpdE protein, measuring diguanylate cyclase activity of the SpdE protein; and comparing the diguanylate cyclase activity of the SpdE protein to a control. The methods can utilize isolated SpdE protein or a cell expressing a SpdE protein. | 2021-01-14 |
20210010058 | QUANTIFICATION OF NUCLEOSOME MODIFICATIONS USING CHEMICALLY-DEFINED RECOMBINANT NUCLEOSOMES - The invention relates to the use of recombinant/semi-synthetic nucleosomes carrying histone and/or DNA modifications as a reference standard for quantification of covalently modified (on the histone proteins or wrapping DNA), variant, or mutant nucleosomes (collectively “modified nucleosomes” or “nucleosome modifications”) from a biological sample. The invention further relates to methods of using the assay to accurately quantify single or combinatorial nucleosome modifications as biomarkers of disease. | 2021-01-14 |
20210010059 | MICROFLUIDIC SYSTEM FOR AMPLIFYING AND DETECTING POLYNUCLEOTIDES IN PARALLEL - The present technology provides for an apparatus for detecting polynucleotides in samples, particularly from biological samples. The technology more particularly relates to microfluidic systems that carry out PCR on nucleotides of interest within microfluidic channels, and detect those nucleotides. The apparatus includes a microfluidic cartridge that is configured to accept a plurality of samples, and which can carry out PCR on each sample individually, or a group of, or all of the plurality of samples simultaneously. | 2021-01-14 |
20210010060 | Highly Multiplexed PCR with Bioinformatically Optimized Primers to Prepare Targeted Libraries for Next-Generation Sequencing - Methods for obtaining libraries of multiple amplicons of target sequences with self-checking controls and sequences. Iterative bioinformatic methods for primer design with self-checking controls for optimized use of sequencing resources. Reagent cocktails for enrichment of target sequences. | 2021-01-14 |
20210010061 | METHOD AND APPARATUS TO NORMALIZE QUANTITATIVE READOUTS IN SINGLE-CELL EXPERIMENTS - Provided herein are methods and systems for detection of nucleic acids for single cell samples. As part of the detection, a unique step of normalization of different single cell samples is included. One embodiment of the method includes i) selecting one or more target nucleic acid sequence of interest in an individual cell, where the target nucleic acid sequence is complementary to a nucleic acid in a cell; ii) providing a sample having a plurality of individual single cells and encapsulating one or more individual cell(s); iii) providing a sample normalization component to one or more encapsulated cell, where the normalization component comprises an exogenous nucleic acid having a known sequence; iv) providing nucleic acid primers for the target nucleic acid and the exogenous nucleic acid; v) providing a protease to each encapsulated cell and incubating the encapsulated cell with the protease in the drop to produce a cell lysate; vi) performing a nucleic acid amplification reaction to form an amplification product from the nucleic acid of a single cell, where the amplification product comprise amplicons of one or more target nucleic acid sequence and an amplicon for the exogenous nucleic acid; and vii) comparing the amplification products from the target amplicons and the exogenous nucleic acid amplicons and determining the copy number or sequence of the target nucleic acid in a single cell. | 2021-01-14 |
20210010062 | METHOD FOR ANALYZING AN INTERACTION EFFECT OF NUCLEIC ACID SEGMENTS IN NUCLEIC ACID COMPLEX - Provided is a method of analyzing interactions between nucleic acid segments in a nucleic acid complex. Specifically, restriction enzymes that recognize four-base site are used for digestion, followed by a two-step ligation method. The overall process is simple and easy to control, realizing the efficient and sensitive detection of nucleic acid interaction segments. | 2021-01-14 |
20210010063 | BARCODED MOLECULAR STANDARDS - High throughput personal genomic testing has created a need for robust quality control mechanisms to track sample identity, reagent integrity, and other factors with significant influence on assay performance. A method of massively parallel sequencing using an accompanying barcoded molecular standard enables one to track nucleic acid analytes to identify them by project, lot, batch, or patient. The molecular standard contains sequences present in the analyte, allowing it to be processed simultaneously without any other additional reagents. Within the molecular standard, a calibrator sequence permits assessment of fidelity of sequence determination. Additional sequences in the molecular standard may be used to manipulate the molecular standard separate from the analyte. The molecular standard can be used to benchmark sequencing platforms and assess error rates. | 2021-01-14 |
20210010064 | ENRICHMENT OF NUCLEIC ACIDS - Provided are methods directed to enriching nucleic acids in a biological sample. These methods, in some embodiments can discriminately enrich the abundance of low-copy nucleic acids relative to higher-copy nucleic acids. In some embodiments, the methods provided can enrich a low-copy number mutant allele associated with a disease state, thus allowing early detection and optimized treatment. In other embodiments, the methods can be used for detection of particular molecules, such as antigens, in a sample. | 2021-01-14 |
20210010065 | METHODS AND REAGENTS FOR ENRICHMENT OF NUCLEIC ACID MATERIAL FOR SEQUENCING APPLICATIONS AND OTHER NUCLEIC ACID MATERIAL INTERROGATIONS - The present technology relates generally to methods and compositions for targeted nucleic acid sequence enrichment, as well as uses of such enrichment for error-corrected nucleic acid sequencing applications and other nucleic acid sequence interrogations. In some embodiments, provided methods provide non-amplification based targeted enrichment strategies compatible with the use of molecular barcodes for error correction. Other embodiments provide methods for non-amplification based targeted enrichment strategies compatible with direct digital sequencing (DDS) and other sequencing strategies (e.g., single molecule sequencing modalities and interrogations) that do not use molecular barcoding. | 2021-01-14 |
20210010066 | DEVICES AND METHODS FOR NUCLEIC ACID IDENTIFICATION - Discussed herein are devices and methods for obtaining nucleotide sequence information from nucleic acid and nucleic acid samples. The device includes a fluidic channel that aids in manipulating a sample as the sample flows through various zones of the channel. Provided herein are methods for nucleic acid analysis that help to identify and filter out molecules that are in non-ideal conformations such as being folded, kinked, or overlapping with other molecules. | 2021-01-14 |
20210010067 | KITS AND METHODS FOR ASSESSING A CONDITION OR A RISK OF DEVELOPING A CONDITION, AND RELATED METHODS OF TREATMENT - Provided herein are kits and methods for detecting, monitoring, and classifying a nongonococcal urethritis (NGU) infection in a male subject based on a genitourinary microbiome of a subject, as well as related methods of treating. | 2021-01-14 |
20210010068 | METHODS AND SYSTEMS FOR DETERMINING SPATIAL PATTERNS OF BIOLOGICAL TARGETS IN A SAMPLE - The present disclosure provides methods and assay systems for use in spatially encoded biological assays, including assays to determine a spatial pattern of abundance, expression, and/or activity of one or more biological targets across multiple sites in a sample. In particular, the biological targets comprise proteins, and the methods and assay systems do not depend on imaging techniques for the spatial information of the targets. The present disclosure provides methods and assay systems capable of high levels of multiplexing where reagents are provided to a biological sample in order to address tag the sites to which reagents are delivered; instrumentation capable of controlled delivery of reagents; and a decoding scheme providing a readout that is digital in nature. | 2021-01-14 |
20210010069 | METHOD TO QUANTIFY TELOMERE LENGTH AND GENOMIC MOTIFS - The present invention provides novel compositions and methods for assessing the size of tandem repeat sequences, e.g., telomeres, within a genome, using specially designed Molecular Inversion Probes (MIPs) and reaction conditions. | 2021-01-14 |
20210010070 | METHOD FOR TRANSPOSASE-MEDIATED SPATIAL TAGGING AND ANALYZING GENOMIC DNA IN A BIOLOGICAL SAMPLE - The present disclosure relates to materials and methods for spatially analyzing nucleic acids that have been fragmented with a transposase enzyme, alone or in combination with other types of analytes. | 2021-01-14 |
20210010071 | KINETIC EXCLUSION AMPLIFICATION OF NUCLEIC ACID LIBRARIES - An example method includes reacting a first solution and a different, second solution on a flow cell by flowing the first solution over amplification sites on the flow cell and subsequently flowing the second solution over the amplification sites. The first solution includes target nucleic acids and a first reagent mixture that comprises nucleoside triphosphates and replication enzymes. The target nucleic acids in the first solution transport to and bind to the amplification sites at a transport rate. The first reagent mixture amplifies the target nucleic acids that are bound to the amplification sites to produce clonal populations of amplicons originating from corresponding target nucleic acids. The amplicons are produced at an amplification rate that exceeds the transport rate. The second solution includes a second reagent mixture and lacks the target nucleic acids. The second solution is to increase a number of the amplicons at the amplification sites. | 2021-01-14 |
20210010072 | DEVICE, PREPARATOR'S SKILL EVALUATING METHOD, NON-TRANSITORY RECORDING MEDIUM STORING COMPUTER PROGRAM FOR EVALUATING SKILL OF PREPARATOR, AND PREPARATOR'S SKILL EVALUATING DEVICE, AND TESTING DEVICE PERFORMANCE EVALUATING METHOD, NON-TRANSITORY RECORDING MEDIUM STORING COMPUTER PROGRAM FOR EVALUATING PERFORMANCE OF TESTING DEVICE, AND TESTING DEVICE PERFORMANCE EVALUATING DEVICE - Provided is a device including: a plurality of wells; a reagent composition located in each of the wells and containing an amplifiable reagent in a specific copy number; and two or more groups into which the wells are divided to have the amplifiable reagent located in the same specific copy number but to be varied in composition of the reagent composition except for the specific copy number. Preferably, composition except for the specific copy number of the amplifiable reagent includes at least any one of primer and amplifying reagent. More preferably, the device includes two or more groups varied in the specific copy number. Yet more preferably, the groups of wells include at least a negative control group in which the specific copy number of the amplifiable reagent is 0, and a group in which the specific copy number of the amplifiable reagent is close to the limit of detection. | 2021-01-14 |
20210010073 | PREPARATION OF NUCLEIC ACID LIBRARIES FROM RNA AND DNA - Some embodiments of the methods and compositions provided herein relate to the preparation and use of nucleic acid libraries derived from RNA and DNA. In some embodiments, a nucleic acid library can be prepared by tagging polynucleotides derived from RNA. Some embodiments include the analysis of sequence data from such libraries. | 2021-01-14 |
20210010074 | METHODS OF DETERMINING NUCLEIC ACID STRUCTURAL INFORMATION - Methods of double-stranded nucleic acid sequence determination and assembly that are able to identify insertions, deletions, repeat region sizes and genomic rearrangements, for example, are disclosed herein, which can use relatively large labeled nucleic acid fragments to analyze the structure of even larger genetic regions. In some embodiments these methods involve the use of certain parameters which unexpectedly improve overall method performance. In some embodiments these methods involve sample labeling that does not result in the formation of single-stranded nucleic acid fragment labeling intermediaries. | 2021-01-14 |
20210010075 | RNA SEQUENCING METHODS - Described herein are methods for determining a sequence of a region of interest from an mRNA molecule. Sequenced polynucleotides can include a barcode region, a homopolymer region (e.g., a poly-A region), and a target region associated with the mRNA molecule. According to some methods, the barcode region omits the same base present in the homopolymer region. According to some methods, extension of the primer used for sequencing is stalled within the homopolymer region. According to some methods, sequencing flow cycles and the different barcode regions of the polynucleotides configured are such that the primer is extended to the end of the barcode region across the plurality of polynucleotides before being extended into the homopolymer region. According to some methods, two primers or a cleavable primer is used to separately sequence the barcode region and the target region. | 2021-01-14 |
20210010076 | METHODS AND SYSTEMS FOR ABNORMALITY DETECTION IN THE PATTERNS OF NUCLEIC ACIDS - Systems, media, methods, and kits disclosed herein can improve analysis capabilities of genomic materials. Results from such analyses can be used to detect genomic biomarkers in one or more genomic materials. The systems, media, methods and kits disclosed herein can identify changes or patterns among samples, and can employ machine learning methods to explore changes or potential changes in biological conditions or risks thereof. Further, the systems, media, methods and kits disclosed herein can utilize machine learning algorithms to analyze samples with high accuracy. | 2021-01-14 |